DGAP-News: CureVac / Key word(s): Study/Research Update 
CureVac's COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection Against SARS-CoV-2 B.1.351 Variant (South African 
Variant) in Preclinical Challenge Study 
2021-03-23 / 13:00 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
CureVac's COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection Against 
SARS-CoV-2 B.1.351 Variant (South African Variant) in Preclinical Challenge Study 
- First challenge infection study in preclinical mouse model to provide evidence for protection against SARS-CoV-2 
variant 
- CVnCoV induces robust antibody titers with virus variant neutralizing capacity in immunized animals 
- Full protection of immunized mice from infection and mortality during variant challenge infection 
TÜBINGEN, Germany/ BOSTON, USA - March 23, 2021 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company 
developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced the 
publication of preclinical data demonstrating that their COVID-19 vaccine candidate, CVnCoV, protects against challenge 
infections with the SARS-CoV-2 Variant of Concern B.1.351 (also referred to as the "South African" variant) and a 
strain of the original SARS-CoV-2 B1 lineage (BavPat1) in a transgenic mouse model. Consistent with available variant 
studies, the neutralization capacity of robust antibody titers was shown to be impacted by the B.1.351 variant compared 
to the original strain. However, vaccinated animals were fully protected from lethal challenge infections with both 
strains. The full manuscript of the preclinical data is available on the bioRxiv preprint server. 
"Emergence of new SARS-CoV-2 strains, which exhibit the potential to escape an existing SARS-CoV-2 immunity, pose an 
increasing risk to the progress of current global immunization efforts," said Igor Splawski, Ph.D., Chief Scientific 
Officer of CureVac. "To our knowledge, this is the first challenge study in a human ACE2 transgenic mouse model of 
severe disease that shows complete protection against one of the most threatening virus variants." 
Within the study, transgenic mice expressing the human ACE2 receptor, the receptor through which SARS-CoV-2 enters 
human cells, were immunized with 8µg of CVnCoV per dose, following a two-dose vaccination schedule at day 0 and day 28. 
Vaccination resulted in robust antibody responses and complete protection (100% survival) against the original 
SARS-CoV-2 strain and also B.1.351 (variant strain first identified in South Africa) challenge infections. CVnCoV 
vaccination efficiently blocked viral replication of B.1.351 in the lower respiratory tract and brain, and reduced 
viral replication in the upper respiratory tract in vaccinated and challenged animals. 
About CVnCoV 
CureVac began development of its mRNA-based COVID-19 vaccine candidates in January 2020. The vaccine candidate chosen 
first for clinical development, CVnCoV, is an optimized, non-chemically modified mRNA, encoding the prefusion 
stabilized full-length spike protein of the SARS-CoV-2 virus, and formulated within Lipid Nanoparticles (LNPs). Phase 1 
and 2a clinical trials of CVnCoV began in June and September 2020, respectively. Phase 1 interim data reported in 
November 2020 showed that CVnCoV was generally well tolerated across all tested doses and induced strong antibody 
responses in addition to first indication of T cell activation. The quality of immune response was comparable to 
recovered COVID-19 patients, closely mimicking the immune response after natural COVID-19 infection. In December 2020, 
CureVac initiated a pivotal Phase 2b/3, the HERALD study, with a 12µg dose of CVnCoV. In February 2021, CureVac 
initiated a rolling submission with the European Medicines Agency (EMA) for CVnCoV. 
CureVac has entered into several strategic partnerships for the further development, production and commercialization 
of CVnCoV. The company entered into a collaboration agreement with Bayer in January 2021 with regards to CureVac's 
current vaccine candidate CVnCoV. In February 2021, CureVac and the British pharmaceutical company GlaxoSmithKline 
(GSK) agreed to jointly develop next-generation multi-valent mRNA vaccines against COVID-19. The development of new 
vaccine candidates is strengthened by a partnership with the UK Government and its Vaccines Taskforce, which CureVac 
also entered in February 2021. GSK will also potentially contribute to this collaboration. Clinical trial and 
commercial material is provided by the company's substantial production capacities for mRNA vaccines at its 
headquarters in Tübingen, supported by the current expansion of manufacturing capacities in Europe, allowing 
broad-scale manufacturing of CVnCoV for potential commercial supply preparedness. 
About CureVac 
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years 
of expertise in developing and optimizing the versatile biological molecule for medical purposes. The principle of 
CureVac's proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human 
body to produce its own proteins capable of fighting a broad range of diseases. Based on its proprietary technology, 
the Company has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody 
therapies, and the treatment of rare diseases. CureVac had its initial public offering on the New York Nasdaq in August 
2020. It is headquartered in Tübingen, Germany, and employs more than 600 people at its sites in Tübingen, Frankfurt, 
and Boston, USA. Further information can be found at www.curevac.com. 
CureVac Media Contact 
Thorsten Schüller, Vice President Communications 
CureVac, Tübingen, Germany 
T: +49 7071 9883-1577 
thorsten.schueller@curevac.com 
CureVac Investor Relations Contact 
Dr. Sarah Fakih, Vice President Investor Relations 
CureVac, Tübingen, Germany 
T: +49 7071 9883-1298 
M: +49 160 90 496949 
sarah.fakih@curevac.com 
Forward-Looking Statements 
This press release contains statements that constitute "forward looking statements" as that term is defined in the 
United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, 
expectations, beliefs, plans, objectives, assumptions or projections of CureVac (the "company") regarding future events 
or future results, in contrast with statements that reflect historical facts. Examples include discussion of the 
potential efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, 
growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology 
such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," or "expect," "may," "will," "would," 
"could," "potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking 
statements are based on management's current beliefs and assumptions and on information currently available to the 
company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not 
place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other 
variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the 
worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and 
clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and 
collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in 
current and proposed legislation, regulations and governmental policies, pressures from increasing competition and 
consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of 
operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability 
to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other 
factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place 
undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual 
results to differ materially from those it thought would occur. The forward-looking statements included in this press 
release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation 
to update any such statements or to publicly announce the results of any revisions to any such statements to reflect 
future events or developments, except as required by law. 
For further information, please reference the company's reports and documents filed with the U.S. Securities and 
Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov 
=---------------------------------------------------------------------------------------------------------------------- 
2021-03-23 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      CureVac 
              Friedrich-Miescher-Str. 15 
              72076 Tübingen 
              Germany 
EQS News ID:  1177545 
 
End of News   DGAP News Service 
=------------

(MORE TO FOLLOW) Dow Jones Newswires

March 23, 2021 08:01 ET (12:01 GMT)